News | January 29, 2024
Jubilant Pharmova Singapore to sell its entire 25.8% stake in Sofie Biosciences, USA
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Subscribe To Our Newsletter & Stay Updated
